Viekira Pak Liver Injuries | Technivie Liver Injuries | Lawsuit, Lawyer, Attorney

Viekira Pak Liver Injuries | Technivie Liver Injuries | Lawsuit, Lawyer, Attorney

Viekira Pak Liver Injuries, Technivie Liver Injuries, Viekira Pak Liver Injuries Lawsuit, Technivie Liver Injuries Lawsuit, Viekira Pak Liver Injuries Lawyer, Technivie Liver Injuries Lawyer, Viekira Pak Liver Injury Attorney, Technivie Liver Injury Attorney

viekira-pak-liver-injuries-technivie-liver-injuries-lawsuit-lawyer-attorneyDid you or a loved one sustain a serious injury while undergoing treatment with Viekira Pak or Technivie for hepatitis C? In October 2015, the U.S. Food & Drug Administration (FDA) issued a Drug Safety Communication to warn that these therapies had been linked to serious liver injuries in patients with underlying advanced liver disease. Some of these Viekira Pak liver injury cases and Technivie liver injury cases resulted in a need for liver transplantation or death. In response, the FDA ordered AbbVie, Inc., the manufacturer of both drugs, to add new information about this safety risk to their labels.

Southern Med Law is now offering free, no-obligation case reviews to anyone who suffered serious liver injuries which could be associated with Viekira Pak and Technivie, including:

  • Hepatic decompensation
  • Liver failure

Viekira Pak Liver Injuries Lawsuits and Technivie Liver Injuries Lawsuits for individuals who were seriously injured

As both an attorney and practicing physician, Dr. François Blaudeau, the founder of Southern Med Law, possesses a unique understanding of the medical and legal issues faced by individuals who may have been harmed by these medications. If you are interested in pursuing a Viekira Pak or Technivie lawsuit on behalf of yourself or a loved one, please contact Dr. Blaudeau and the legal staff at Southern Med Law to learn more about your legal rights today.

Viekira Pak and Technivie

Approved by the FDA in December 2014, Viekira Pak is indicated for use in patients with genotype 1 chronic hepatitis C infections, including those with compensated cirrhosis. Technivie was launched in July 2015 and is approved for treatment of patients with genotype 4 chronic hepatitis C virus infection without cirrhosis. Both medications reduce the amount of hepatitis C virus in the body by preventing the virus from multiplying, and may slow down the disease. Side effects commonly associated with their use include nausea, itching, and sleep problems.

An estimated 10,104 patients in the U.S. filled prescriptions for Viekira Pak between December 2014 and August 2015. No prescription data is yet available for Technivie.

Viekira Pak Liver Injury Reports and Technivie Liver Injury Reports

According to the FDA’s Drug Safety Communication, 26 cases of liver failure and hepatic decompensation that were reported to the agency’s Adverse Event Reporting System between December 2014 and July 2015 are considered possibly or probably related to Viekira Pak or Technivie. The reports indicated that 10 patients experienced liver failure resulting in transplantation or death, and 16 patients experienced various degrees of liver dysfunction. In most of the cases, liver injury occurred within 1 to 4 weeks of starting treatment. Serious outcomes were reported mostly in patients taking Viekira Pak who had evidence of advanced cirrhosis even before treatment was initiated.

The FDA is requiring AbbVie to include information about serious liver injuries to the Contraindications, Warnings and Precautions, Postmarketing Experience, and Hepatic Impairment sections of the Viekira Pak and Technivie drug labels. Patients using these medications have been advised to contact their health care professional immediately if they develop signs of serious liver injury, including:

  • Fatigue
  • Weakness
  • Loss of appetite
  • Nausea and vomiting
  • Yellow eyes or skin
  • Light-colored stools

Patients should not stop taking Viekira Pak or Technivie without consulting their doctor, as stopping treatment early may result in drug resistance to other hepatitis C medicines.

Legal Help for Victims of Viekira Pak Liver Injuries or Technivie Liver Injuries

Southern Med Law has worked hard to develop a strong reputation in healthcare litigation. It is Southern Med Law’s first-hand knowledge of medicine that has made the law firm an aggressive and effective advocate for those who were harmed due to negligent pharmaceutical manufacturers. If you or a loved one suffered Viekira Pak Liver Injuries or Technivie Liver Injuries, please contact Southern Med Law today to learn more about your legal rights. You can arrange for a free, no obligation Viekira Pak Liver Injuries or Technivie Liver Injuries lawsuit review by filling out our online form, or by calling the office directly at 205-547-5525.

Viekira Pak Liver Injuries or Technivie Liver Injuries Info Links

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm468757.htm

http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm